Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus

被引:304
作者
Charles, PGP
Ward, PB
Johnson, PDR
Howden, BP
Grayson, ML
机构
[1] Austin Hlth, Dept Infect Dis, Heidelberg, Vic 3084, Australia
[2] Austin Hlth, Dept Microbiol, Heidelberg, Vic 3084, Australia
关键词
D O I
10.1086/381093
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We assessed all episodes of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia at our hospital during a 12-month period (n = 53) and compared those due to heterogeneous vancomycin-intermediate S. aureus (hVISA; n=5, 9.4%) with those due to vancomycin-susceptible MRSA (n = 48). Patients with hVISA bacteremia were more likely to have high bacterial load infections (P = .001), vancomycin treatment failure (persistent fever and bacteremia for >7 days after the start of therapy; P < .001), and initially low serum vancomycin levels (P = .006). These clinical markers of hVISA bacteremia may help focus diagnostic efforts and treatment.
引用
收藏
页码:448 / 451
页数:4
相关论文
共 18 条
  • [1] Vancomycin in surgical infections due to meticillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin
    Ariza, J
    Pujol, M
    Cabo, J
    Peña, C
    Fernández, N
    Liñares, J
    Ayats, J
    Gudiol, F
    [J]. LANCET, 1999, 353 (9164) : 1587 - 1588
  • [2] Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001
    Fridkin, SK
    Hageman, J
    McDougal, LK
    Mohammed, J
    Jarvis, WR
    Perl, TM
    Tenover, FC
    [J]. CLINICAL INFECTIOUS DISEASES, 2003, 36 (04) : 429 - 439
  • [3] Fridkin SK, 2001, CLIN INFECT DIS, V32, P108, DOI 10.1086/317542
  • [4] Emergence of heterogeneous intermediate vancomycin resistance in Staphylococcus aureus isolates in the Dusseldorf area
    Geisel, R
    Schmitz, FJ
    Thomas, L
    Berns, G
    Zetsche, O
    Ulrich, B
    Fluit, AC
    Labischinsky, H
    Witte, W
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 (06) : 846 - 848
  • [5] Hiramatsu K, 2001, Lancet Infect Dis, V1, P147, DOI 10.1016/S1473-3099(01)00091-3
  • [6] Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin
    Hiramatsu, K
    Aritaka, N
    Hanaki, H
    Kawasaki, S
    Hosoda, Y
    Hori, S
    Fukuchi, Y
    Kobayashi, I
    [J]. LANCET, 1997, 350 (9092) : 1670 - 1673
  • [7] Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility
    Hiramatsu, K
    Hanaki, H
    Ino, T
    Yabuta, K
    Oguri, T
    Tenover, FC
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (01) : 135 - 136
  • [8] Staphylococcus aureus with heterogeneous resistance to vancomycin:: Epidemiology, clinical significance, and critical assessment of diagnostic methods
    Liu, C
    Chambers, HF
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (10) : 3040 - 3045
  • [9] Harmonization of pulsed-field gel electrophoresis protocols for epidemiological typing of strains of methicillin-resistant Staphylococcus aureus:: a single approach developed by consensus in 10 European laboratories and its application for tracing the spread of related strains
    Murchan, S
    Kaufmann, ME
    Deplano, A
    de Ryck, R
    Struelens, M
    Zinn, CE
    Fussing, V
    Salmenlinna, S
    Vuopio-Varkila, J
    El Solh, N
    Cuny, C
    Witte, W
    Tassios, PT
    Legakis, N
    van Leeuwen, W
    van Belkum, A
    Vindel, A
    Laconcha, I
    Garaizar, J
    Haeggman, S
    Olsson-Liljequist, B
    Ransjo, U
    Coombes, G
    Cookson, B
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (04) : 1574 - 1585
  • [10] Standards NCfCL, 2000, M7A5 NCCLS